TRAP5b was measured using the IS4100 and control kit (detection limit 0.9 IU/l, CV 5.0-13.6%). P1NP was measured using the IS4000 and control kit (detection limit 2 ng/ml, CV4,4-5.3%). Intact PTH was measured using the IS3200 and control kit (detection limit 5 pg/ml, CV 4.1-8.2%). Procollagen type 1 N-terminal peptide (P1NP), Tartrate-resistant phosphatase type 5b (TRAP5b – iSYS), and intact PTH were determined using an iSys machine and kits from IDS plc. CV was 1.7-7.8 % for intra-assay and CV 2.2-10.7 % for inter-assay variation. Serum vitamin D was measured using an electrochemiluminescence-binding assay ECLIA (Elecsys® Vitamin D total, modular analytics E170). Samples were immediately frozen at -80 ☌. The coefficient of variation (CV) between the two scanners was 1%.
Quality control procedures were run every day including calibration by use of QA Phantom (Lunar DPX Series QC Phantom and a Block Phantom). Bone mineral densityīone Densitometry (BMD) of total hip, femoral neck, and lumbar spine (L1-L4) was assessed for all subjects at baseline and after 12 months using by dual-energy x-ray absorptiometry (DXA) scans on a GE Lunar Prodigy Scanner (GE Healthcare Lunar prodigy, USA). osteoarthritis) or sensory dysfunction (e.g. 10) The presence of other pain problems (e.g. 9) Individuals who cannot stand up and stand still without support or a helping device due to physically impairment. 8) Individuals that have been taking other antidepressants than citalopram or mirtazapine for more than 6 months prior to the inclusion and if this treatment persisted for a period of minimum 12 months.
individuals diagnosed with dementia, severely psychotic or depressed individuals.
7) Individuals which is not considered eligible for the clinical trial e.g. 6) Individuals diagnosed with a disease that affects bone such as Paget’s disease of the bone, or fibrous dysplasia. 5) Individuals with prosthetic material in hip or spine. 4) Individuals diagnosed with cancer or a metabolic disorder such as diabetes. 2) Impaired renal function (serum creatinine > 150 micromolar/l). Results: Serum 25(OH)D levels increased in the vitamin D treated patients compared with controls at the 12 months visit (P35 micrograms daily, depot Medroxyprogesterone Acetate (DMPA), Cyclosporine (CsA), Antiretroviral Therapy (ART). Physical performance was assessed by Timed up and go, isomeric handgrip exercise, and postural control by force plate. Degree of depression by the Major Depression Inventory. Pain sensitivity measures based on pain detection thresholds by cuff algometry, temporal summation of pain, conditioned pain modulation, and cutaneous pain sensitivity by pinprick test. Serum 25-hydroxyvitamin D, intact-Parathyroid Hormone, type 1 procollagen N terminal peptide, tartrate resistant acid phosphatase type 5b.
Measurements: Bone Densitometry by dual-energy x-ray absorptiometry. Intervention: Participants received daily vitamin D supplementation (50 micrograms) or placebo in one year.
Participants: A total of 21 patients and 50 controls. Setting: A study of Danish women in the age 50 to 90 years. Design: Randomised double blind placebo controlled trial. Objectives: To study the pleiotropic effects of daily vitamin D supplementation in depressed patients treated with citalopram (patients) and healthy controls. Department of Endocrinology, Aalborg University Hospital, Aalborg, DenmarkĬorresponding Author: Stine Aistrup Eriksen, PhD, Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark, Phone: +45 23 98 60 72īackground: Antidepressants may increase the risk of fractures through negative effects on the musculoskeletal system that could be hindered by vitamin D supplements. Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Aalborg University, Aalborg, Denmark 5. SMI, Department of Health Science and Technology, Aalborg University, Aalborg, Denmark 4. Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark 3. Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark 2.